Medical Oncologist
Biomarker & Molecular Testing
Germline vs Somatic Testing: — The Difference That Actually Matters
These two tests answer completely different questions. Germline testing asks whether your family carries a mutation that raises cancer risk. Somatic testing asks what is driving the cancer you have now. Getting the wrong one done — or only one when you need both — delays the right treatment.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Different samples, different answers — Germline uses blood or saliva. Somatic needs tumour tissue. The results do not overlap in what they tell you.
- Most treatment decisions need somatic — Targeted therapy choices — for EGFR, KRAS, HER2, BRCA — are usually made from somatic testing of the tumour.
- Germline has family implications — A positive germline result means your blood relatives may need screening, not just you.
- Some patients need both — A BRCA mutation found on somatic testing in breast or ovarian cancer often prompts a germline test as a follow-up.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Germline testing looks for mutations you were born with — the type that can run in families. Somatic testing maps the mutations that have developed inside your tumour and guide your treatment choices. Most people with cancer need somatic testing. Germline testing is added when your cancer type or family history suggests a hereditary risk.
Germline vs somatic: what each one actually tests
| Germline testing | Somatic testing | |
|---|---|---|
| What is tested | Your inherited DNA — the same in every cell in your body | Mutations that have developed inside the tumour cells only |
| Sample source | Blood or saliva — a new procedure is rarely needed | Tumour biopsy or surgical specimen |
| What the result reveals | Whether you carry a mutation you were born with | The molecular changes driving your specific cancer right now |
| Who is affected by the result | You and your blood relatives | Your treatment plan — family cancer risk is not assessed |
| When it is typically ordered | Young age at diagnosis, specific cancer types, family history of cancer | Before starting systemic treatment in most solid tumours |
| Turnaround | Several weeks for most panels | Several weeks; large comprehensive panels may take longer |
| Indicative cost | Varies by genes tested; single-gene tests cost less than multi-gene panels | Varies; comprehensive next-generation sequencing panels cost more than targeted single-gene tests |
How do you know which test you need?
Most people being treated for cancer need somatic testing. It tells your oncologist which mutations are driving the tumour and whether targeted therapies are likely to work. For most solid tumours, this testing is now part of the standard workup before systemic treatment begins.
Germline testing becomes relevant when there is a reason to suspect a hereditary component. A personal history of cancer at a young age, certain cancer types such as ovarian or triple-negative breast cancer, or a family with multiple affected relatives are the situations where it adds information that somatic testing alone cannot provide.
When somatic testing finds a mutation in a gene like BRCA1 or BRCA2, many oncologists will follow up with germline testing. The answer changes what your family members should do — even if it does not change your own treatment.
Which test is likely to apply to you
- Your oncologist is choosing between targeted therapies → somatic testing is what guides that decision
- You have ovarian, fallopian tube, or peritoneal cancer → ask about germline testing alongside somatic
- You have triple-negative breast cancer → germline BRCA testing is recommended by ASCO and ESMO alongside somatic profiling
- A close relative has tested positive for BRCA1, BRCA2, Lynch syndrome, or another hereditary mutation → germline testing applies to you directly
- You are being considered for a PARP inhibitor → germline BRCA status is part of eligibility in many settings
- Your somatic result found a BRCA or mismatch repair gene mutation → ask whether a germline test is now indicated
- Your cancer was diagnosed before age 50 and a close relative has had the same or a related cancer → raise germline testing at your next appointment
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What if your oncologist has not mentioned one of these?
Somatic testing is routinely ordered because it directly guides treatment. Germline testing requires an additional conversation — it has implications for your family, and in many settings genetic counselling is recommended alongside it.
If you recognise yourself in the checklist above, raise it directly. Ask: 'Is germline testing indicated for me, and if not, what is the reason?' That is a reasonable question and your oncologist should be able to explain the thinking.
If germline testing is indicated and has not been done, you have not missed your window. It can be arranged at any point in your care.
What people ask once they understand the difference
Can somatic results tell me if my children are at risk?
Not reliably. A somatic test is done on tumour tissue, so the mutations it finds could be ones that developed only in the cancer, not ones your children might inherit. If you want to know whether your children have a hereditary risk, that answer comes from germline testing — which looks at your constitutional DNA rather than the tumour's. If your somatic result found a mutation in a known hereditary gene like BRCA1, BRCA2, or a mismatch repair gene, ask your oncologist whether germline testing is now recommended.
I had germline testing that came back negative. Do I still need somatic testing?
Yes. These tests answer different questions, so a negative germline result does not replace somatic testing. Germline testing tells you what you were born with. Somatic testing tells you what has happened inside the tumour. A cancer can carry targetable somatic mutations even when no hereditary mutation was found. Your oncologist needs the somatic result to decide which treatments are most likely to work, regardless of what the germline test showed.
My somatic test found a BRCA mutation. Does that mean it is hereditary?
Not necessarily. BRCA mutations can arise in tumours without being inherited — this is called a somatic BRCA mutation. The only way to know whether yours is inherited is to do a germline test on your blood or saliva. The answer matters because an inherited mutation means your blood relatives have an elevated risk and should consider screening. ASCO and ESMO guidance supports germline follow-up testing in this situation for certain cancer types — ask your oncologist whether it applies to you.
Does it matter which laboratory does the test?
It matters more than most people realise. Germline testing should be done in a laboratory accredited for hereditary cancer testing, and the result is ideally interpreted alongside a genetic counsellor. Somatic testing quality depends on the depth of sequencing and the panel used — a small targeted panel gives less information than a comprehensive next-generation sequencing panel. Ask your oncologist which laboratory they work with and whether the panel covers the genes most relevant to your cancer type.
What is a variant of uncertain significance, and should I be worried?
A variant of uncertain significance, or VUS, means the laboratory found a change in a gene but does not yet have enough evidence to say with certainty whether it raises cancer risk. It is neither a clear positive nor a clear negative result. Your oncologist or genetic counsellor will explain whether it changes your management. A VUS classification can be updated as the scientific databases grow — which is one reason to stay in contact with the team that ordered your test rather than treating the result as final.
Did you know?
A proportion of people who carry a hereditary cancer gene mutation have no family history of cancer that would have prompted testing under older guidelines.
This is one reason ASCO and ESMO guidance for certain cancer types — including ovarian cancer and triple-negative breast cancer — now recommends germline testing regardless of family history.
Source: ASCO and ESMO Guidelines on Hereditary Cancer Predisposition Testing
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is somatic testing the same as a liquid biopsy?
Not exactly. Somatic testing refers to testing for tumour mutations — it can be done on tissue from a biopsy or surgery, or on circulating tumour DNA from a blood sample, which is what a liquid biopsy is. Liquid biopsy is one method of performing somatic testing, not a separate category. Tissue-based somatic testing remains the standard when enough tissue is available; liquid biopsy is often used when a re-biopsy would be difficult or when monitoring is needed over time.
How long do results from each test take?
Both typically take several weeks from when the laboratory receives the sample. Somatic testing using large comprehensive panels can take longer than single-gene tests. Your oncology team will give you the specific turnaround estimate for the test being ordered, because it depends on the laboratory and the panel. If your treatment decision is time-sensitive, ask which result is needed first and whether an expedited option is available.
Can my family members get germline testing if they do not have cancer?
Yes, and this is precisely the purpose of germline testing for at-risk relatives — identifying a mutation before cancer develops, so that screening and prevention can begin earlier. If a blood relative has already tested positive for a hereditary mutation, targeted testing for that specific mutation in other family members is simpler, quicker, and less expensive than full panel testing. A genetics or oncology team can explain the process for relatives who are not currently being treated.
Will insurance or a government scheme cover these tests?
Coverage varies by insurer, policy, and the scheme you are enrolled in. Somatic testing for treatment-guiding decisions is more commonly covered than germline testing, but this changes frequently and depends on the cancer type and the specific genes being tested. Ask your hospital's patient support team or insurance coordinator before booking — they can tell you what documentation is needed for a coverage claim and which laboratories are on the approved panel.
My cancer has spread. Is somatic testing still worth doing?
Yes, and often more urgently. Somatic testing identifies targetable mutations that guide systemic treatment, and that applies at any stage. Some targeted therapies are specifically approved for advanced disease where earlier treatments have not worked. If somatic testing has not been done, or was done on early-stage tissue some time ago, ask your oncologist whether testing the current disease — ideally on a more recent biopsy — would add useful information.
How is this testing arranged at CION?
Your oncologist will order whichever test is indicated at your consultation. Somatic testing is usually done on tumour tissue from your existing biopsy or surgical specimen, so a new procedure is not always required. For germline testing, a blood sample is taken. Results are reviewed at your next appointment and explained in the context of your treatment plan. If genetic counselling is indicated alongside germline testing, your team will arrange a referral.